Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01371851 · ClinicalTrials.gov registry record · Phase 1
Doxazosin for Psychostimulant Dependence
A Phase 1 study of Methamphetamine or Cocaine Dependence, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT01371851: Completed Phase 1 study of Methamphetamine or Cocaine Dependence, sponsored by University of Arkansas.
NCT01371851 is a Phase 1 study of Methamphetamine or Cocaine Dependence that has completed, run by University of Arkansas. The registered enrollment target is 22 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01371851, a Phase 1 study of Methamphetamine or Cocaine Dependence, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
Psychostimulant dependence is a major public health problem and no medications have been shown to be very effective in treating this disorder. Thus, the investigators wish to study whether a blood pressure drug thought to reduce drug craving through its interaction at particular adrenergic receptors - doxazosin - can dredge cocaine use relative to placebo in psychostimulant dependent participants enrolled in an 8-week, randomized, double blind, placebo-controlled outpatient clinical trial. Our hypothesis is that doxazosin will reduce cocaine use relative to placebo in psychostimulant dependent participants.
Primary Outcome
Urine samples positive for methamphetamine or cocaine via twice-weekly urine drug screens. Weekly urine results data were averaged within subjects and the mean proportion across subjects within each group was calculated for graphic representation.
Conditions Studied
Interventions
- DRUG Doxazosin extended release
Study Locations (1)
Arkansas
- UAMS Psychiatric Research Institute - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2011-06 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
What the finished NCT01371851 record still lists
NCT01371851 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Methamphetamine or Cocaine Dependence appearing as the primary indexed condition, and to 1 intervention - of which Doxazosin extended release is the first listed.
NCT01371851 reports a single indexed study location in Arkansas.
Frequently Asked Questions
What is clinical trial NCT01371851 about?
NCT01371851 is a clinical study titled "Doxazosin for Psychostimulant Dependence". Psychostimulant dependence is a major public health problem and no medications have been shown to be very effective in treating this disorder. Thus, the investigators wish to study whether a blood pressure drug thought to reduce drug craving through its interaction at particular adrenergic receptors...
What is the current status of trial NCT01371851?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2011-06. Estimated completion is 2014-05.
What conditions does trial NCT01371851 study?
This clinical trial studies the following conditions: Methamphetamine or Cocaine Dependence.
What interventions are being tested in trial NCT01371851?
The interventions under investigation include: Doxazosin extended release (DRUG).
Who is sponsoring clinical trial NCT01371851?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01371851 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01371851's enrollment target sits among peer trials
22 1601st of 2000 higher than 386 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia